US Patent

US7683056 — Pyridine derivatives and their use in the treatment of psychotic disorders

Composition of Matter · Assigned to GlaxoSmithKline LLC · Expires 2026-09-15 · 0y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects novel pyridine derivatives, their pharmaceutically acceptable salts or solvates, and pharmaceutical compositions containing them.

USPTO Abstract

There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein all variables are defined herein. Also provided are pharmaceutical compositions containing the same and methods for their use in therapy.

Drugs covered by this patent

Patent Metadata

Patent number
US7683056
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-09-15
Drug substance claim
Yes
Drug product claim
Yes
Assignee
GlaxoSmithKline LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.